Abstract
No abstract available
Funding Information
  • Alzheimer's Disease Neuroimaging Initiative (U01 AG024904, W81XWH-12-2-0012)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • bbVie, Alzheimer’s Association
  • Alzheimer’s Drug Discovery Foundation;
  • Araclon Biotech;
  • BioClinica, Inc.;
  • Biogen; B
  • ristol-Myers Squibb Company
  • CereSpir, Inc.;
  • Cogstate;
  • Eisai Inc.; E
  • lan Pharmaceuticals, Inc.
  • Eli Lilly and Company;
  • EuroImmun; F
  • . Hoffmann-La Roche Ltd. and its affiliated company
  • Genentech, Inc.;
  • Fujirebio;
  • GE Healthcare;
  • IXICO Ltd.; J
  • anssen Alzheimer Immunotherapy Research & Development, LLC.
  • Johnson & Johnson Pharmaceutical Research & Development LLC.;
  • Lumosity;
  • Lundbeck;
  • Merck & Co., Inc.; M
  • eso Scale Diagnostics, LLC.
  • NeuroRx Research;
  • Neurotrack Technologies;
  • Novartis Pharmaceuticals Corporation;
  • Pfizer Inc.;
  • Piramal Imaging;
  • Servier;
  • Takeda Pharmaceutical Company; and
  • Transition Therapeutics. The
  • Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the F
  • oundation for the National Institutes of Health